Published online before print September 19, 2005, doi: 10.1161/CIRCULATIONAHA.105.569129
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:2002-2011.)
© 2005 American Heart Association, Inc.
Interventional Cardiology |
Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression
Implications for Drug-Eluting Stent Design
From Cardiovascular Research, Physiology Institute, and the Center for Integrative Human Physiology (J.S., R.A.L., A.A., D.Z., P.Z., T.F.L., F.C.T.), University of Zurich, and the Department of Cardiology (J.S., T.F.L., F.C.T.), Cardiovascular Center, University Hospital Zürich, Zürich, Switzerland.
Correspondence to Felix C. Tanner, MD, Cardiovascular Research, Physiology Institute, University of Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. E-mail felix.tanner{at}access.unizh.ch
Received January 7, 2005; de novo received June 15, 2005; accepted July 8, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Drugs released from stents affect the biology of vascular cells. We examined the effect of rapamycin and FK-506 on tissue factor (TF) expression in human aortic endothelial cells (HAECs) and vascular smooth muscle cells (HAVSMCs).
Methods and Results— Rapamycin enhanced thrombin- and tumor necrosis factor (TNF)-
–induced endothelial TF expression in a concentration-dependent manner. The maximal increase was 2.5-fold more pronounced than that by thrombin or TNF- alone and was paralleled by a 1.4-fold higher TF surface activity compared with thrombin alone. Rapamycin by itself increased basal TF levels by 40%. In HAVSMCs, rapamycin did not affect thrombin- or TNF-–induced TF expression. In contrast to rapamycin, FK-506 did not enhance thrombin- or TNF-–induced endothelial TF expression. Thrombin induced a transient dephosphorylation of the mammalian target of rapamycin downstream target p70S6 kinase. Rapamycin completely abrogated p70S6 kinase phosphorylation, but FK-506 did not. FK-506 antagonized the effect of rapamycin on thrombin-induced TF expression. Rapamycin did not alter the pattern of p38, extracellular signal–regulated kinase, or c-Jun NH2-terminal kinase phosphorylation. Real-time polymerase chain reaction analysis revealed that rapamycin had no influence on thrombin-induced TF mRNA levels for up to 2 hours but led to an additional increase after 3 and 5 hours.
Conclusions— Rapamycin, but not FK-506, enhances TF expression in HAECs but not in HAVSMCs. This effect requires binding to FK binding protein-12, is mediated through inhibition of the mammalian target of rapamycin, and partly occurs at the posttranscriptional level. These findings may be clinically relevant for patients receiving drug-eluting stents, particularly when antithrombotic drugs are withdrawn or ineffective, and may open novel perspectives for the design of such stents.
Key Words: endothelium • myocardial infarction • signal transduction • stents • thrombosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Percutaneous coronary intervention with stenting of the culprit lesion is the preferred treatment for patients with acute coronary syndromes.1–3 Several clinical trials have demonstrated that drug-eluting stents (DESs) are superior to bare-metal stents (BMSs) by decreasing the restenosis rates as well as major adverse cardiac events.4–6 Rapamycin (sirolimus), a macrocyclic lactone, is used on DESs because the drug inhibits proliferation and migration of vascular smooth muscle cells (VSMCs).7 FK-506 (tacrolimus), a macrolide immunosuppressant, is an alternative drug used with DESs.8,9 Despite reduced restenosis rates, however, stent thromboses have not decreased with DESs compared with BMSs.6,10–12 Indeed, several hundred cases of in-stent thrombosis have been reported with rapamycin-coated stents,13 and results from a recent multicenter registry imply that thrombosis rates with DESs may be higher in "real world" patients than reported in previous clinical trials.14 The reason for the discrepancy between reduced restenosis rates and unaltered or even enhanced thrombosis rates with DESs compared with BMSs is not known.6,12
Several factors are involved in the pathogenesis of in-stent thrombosis. These include procedure-related factors such as mechanical vessel injury or incomplete stent apposition, patient-related factors such as vessel size or coagulation activity, and finally, the thrombogenicity of the stent itself.15 It has not yet been explored, however, whether the drugs used for stent coating could be involved in the development of in-stent thrombosis.15
Tissue factor (TF), a 263-residue, membrane-bound glycoprotein, is a key enzyme in the initiation of coagulation; it activates factor X (FX) by binding activated factor VII (FVIIa), which ultimately leads to thrombin formation. Initiation of coagulation is a key event in the pathogenesis of thrombosis and acute coronary syndromes. Not surprisingly, atheromatous plaques contain a variety of cells expressing TF, including endothelial cells (ECs) and VSMCs. Moreover, TF levels are elevated in the plasma and atherectomy samples from patients with unstable angina.16 Therefore, TF seems to be involved in the development of atherosclerosis and restenosis after percutaneous coronary intervention.17–19 TF may indeed play a major role in stent thrombosis as well. However, the effect of neither rapamycin nor FK-506 on TF expression has been investigated so far. Moreover, the role of the mammalian target of rapamycin (mTOR) in regulating TF expression is also not known. Thus, the present study was designed to investigate the influence of rapamycin and FK-506 on TF expression in human aortic endothelial cells (HAECs) and vascular smooth muscle cells (HAVSMCs).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cell Culture
HAECs and HAVSMCs were cultured as described.20,21 Cells were grown to confluence in 6-cm culture dishes and rendered quiescent for 24 hours before stimulation with thrombin or tumor necrosis factor (TNF)-
(Sigma). Rapamycin, wortmannin (both from Sigma), FK-506 (Alexis), and LY294002 (Cell Signaling) were added to the dishes 60 minutes before stimulation. Cytotoxicity was assessed with a colorimetric assay to detect lactate dehydrogenase release according to the manufacturer’s recommendations (Roche).
Western Blot Analysis and ELISA
Protein expression was determined by Western blot analysis as described.22,23 Cells were lysed in 50 mmol/L Tris buffer, and 30-µg samples were loaded and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to a polyvinylidene difluoride membrane (Millipore) by semidry transfer. Antibody to human TF (American Diagnostica) was used at 1:2000 dilution; antibodies against the phosphorylated Thr-389 residue of p70S6 kinase (S6K), phosphorylated p38 mitogen-activated protein (MAP) kinase (p38), phosphorylated p44/42 MAP kinase (extracellular signal–regulated kinase [ERK]), and phosphorylated c-Jun NH2-terminal kinase (JNK; all from Cell Signaling) were used at 1:3000, 1:1000, 1:5000, and 1:1000 dilution, respectively. Antibodies against total S6K, total p38, total ERK, and total JNK (all from Cell Signaling) were used at 1:3000, 1:2000, 1:10 000, and 1:1000 dilution, respectively. All blots were normalized to -tubulin (aT) expression (1:20 000 dilution, Sigma). Endothelial TF expression was also measured with a commercially available ELISA (American Diagnostica) according to the supplier’s recommendations.
Real-Time PCR Analysis
RNA was extracted and converted to cDNA as described.22 Real-time polymerase chain reaction (PCR) was performed in an MX3000P PCR cycler (Stratagene). All PCR experiments were performed with the SYBR Green JumpStart kit (Sigma). Each reaction (25 µL) contained 2 µL cDNA, 1 pmol of each primer, 0.25 µL of internal reference dye, and 12.5 µL of JumpStart Taq ReadyMix (containing buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase, and JumpStart Taq antibody). Primers for human TF were used as described.22,24 Expression of the ribosomal protein L28 (L28) mRNA was used as a loading control; primers for human L28 were designed as follows: sense primer, 5'-GCATCTGC-AATGGATGGT-3' and antisense primer, 5'-TGTTCTTGCG-GATCATGTGT-3'. The amplification program consisted of 1 cycle at 95°C for 10 minutes; followed by 40 cycles with a denaturing phase at 95°C for 30 seconds, an annealing phase at 60°C for 1 minute, and an elongation phase at 72°C for 1 minute. A melting curve analysis was performed after amplification to verify the homogeneity of the amplicon. For verification of amplicon size, PCR products were analyzed on an ethidium bromide–stained 1% agarose gel. In each real-time PCR run for TF and L28, a calibration curve generated from serial dilutions of a known TF and L28 standard, respectively, was included, and for each sample, the target values were corrected by those for L28.
TF Surface Activity
A colorimetric assay (American Diagnostica) was used to analyze TF surface activity according to the manufacturer’s recommendations, with some modifications as described.22,25 Cells were grown in 6-well plates; after stimulation, cells were washed twice with phosphate-buffered saline and incubated with human FVIIa and FX at 37°C, resulting in the formation of a TF/FVIIa complex at the cell surface. The TF/FVIIa complex converted human FX to FXa, which was subsequently measured by its ability to cleave a chromogenic substrate. Different concentrations of lipidated human TF were used as positive controls to confirm that the obtained results were in the linear range of detection (data not shown).
Proliferation
To examine the effect of rapamycin and FK-506 on EC proliferation, HAECs were seeded on 6-cm dishes at 7000 cells/cm2. After 24 hours, when cells had reached 
50% confluence, they were serum-starved for 24 hours before incubation with rapamycin (10–7 mol/L), FK-506 (10–7 mol/L), or carrier (0.1% dimethyl sulfoxide) in endothelial basal medium (EBM, Clonetics) containing 10% fetal calf serum (FCS). At the indicated times, cells were gently trypsinized and counted in a hemacytometer. Each analysis was performed in duplicate; results are representative of 3 independent experiments.
Apoptosis
To assess induction of apoptosis by rapamycin and FK-506, cells were cultured in chamber slides (Nunc) at 20 000 cells/well for 24 hours before serum-starvation for 24 hours. Cells were then incubated in EBM with 10% FCS containing rapamycin (10–7 mol/L), FK-506 (10–7 mol/L), or carrier (0.1% dimethyl sulfoxide). At the indicated times, cells were fixed with 4% paraformaldehyde and processed for terminal deoxynucleotidyl nick end-labeling (TUNEL) staining with a commercially available kit (Roche) according to the manufacturer’s recommendations. Afterward, cells were counterstained with 4',6 diamidino-2-phenylindole (DAPI; Vector) and counted under a fluorescence microscope. Two hundred cells per time point and condition were counted, and the number of TUNEL-positive cells was assessed.
Statistics
Data are presented as mean±SEM. Unpaired Student t test was used for statistical analysis. A probability value <0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Rapamycin Enhances TF Expression in HAECs but Not HAVSMCs
Stimulation of HAECs with thrombin (1 U/mL) induced TF expression 23-fold as assessed by Western blotting analysis (Figure 1A). Incubation with rapamycin (10–8 to 10–7 mol/L) before stimulation with thrombin resulted in a concentration-dependent enhancement of TF expression (Figure 1A). The maximal increase was observed after 5 hours and was 2.3-fold compared with stimulation with thrombin alone and 51-fold compared with the basal level. Similarly, rapamycin (10–8 to 10–7 mol/L) enhanced TF expression in response to TNF-
(5 ng/mL); this increase was 2.5-fold, resulting in a 35-fold induction compared with the basal level (Figure 1B). ECs express TF only at very low levels under basal conditions,26 and stimulation of HAECs with rapamycin alone increased basal TF expression by 40%, as assessed by Western blotting analysis (Figure 1C), or 25% as assessed by ELISA (Figure 1D). Expression of TF was 45±1 pg per 500 000 cells for control, 57±3 pg per 500'000 cells for rapamycin (10–7 mol/L) alone, 468±29 pg per 500 000 cells for thrombin stimulation, and 702±30 pg/500 000 cells for thrombin stimulation in the presence of rapamycin (Figure 1D). The rapamycin-enhanced increase in thrombin-induced TF expression was paralleled by an increase of TF surface activity, which reached 1.4 times the level induced by thrombin alone (Figure 1E).
|
Similar to HAECs, thrombin (1 U/mL) and TNF- (5 ng/mL) induced TF expression in HAVSMCs. In contrast to HAECs, however, rapamycin did not affect TF expression in response to either mediator in this cell type (Figure 2A and 2B). No cytotoxic effect of rapamycin was observed for any of the concentrations used (n=4, P=NS; data not shown).
|
FK-506 Does Not Affect TF Expression
Incubation with FK-506 (10–8 to 10–7 mol/L) before stimulation with thrombin (1 U/mL, Figure 3A) or TNF- (5 ng/mL, Figure 3B) did not alter TF expression. No cytotoxic effect of FK-506 was observed for any of the concentrations used (n=4, P=NS; data not shown).
|
Rapamycin Enhances TF Expression by Inhibiting mTOR Activity
Phosphorylation of S6K, a downstream target of the mTOR, is frequently used to assess mTOR inhibition by rapamycin.27,28 When stimulated with thrombin (1 U/mL), S6K phosphorylation was transiently decreased after 30 minutes to a minimum of 19% of the basal level (Figure 4A, left). Rapamycin (10–7 mol/L) completely abrogated S6K phosphorylation, in both the presence and absence of thrombin (Figure 4A, right). Similarly, inhibition of phosphatidyl inositol 3-kinase with LY294002 or wortmannin almost completely abrogated S6K phosphorylation, again independent of thrombin stimulation (Figure 4C). In contrast, FK-506 (10–7 mol/L) did not affect phosphorylation of S6K in either the presence or absence of thrombin (Figure 4B).
|
Rapamycin Enhances TF Expression by Binding to FKBP-12
Rapamycin and FK-506 bind to the same intracellular receptor, FK binding protein-12 (FKBP-12). When HAECs were treated with increasing concentrations of FK-506 for 30 minutes before incubation with rapamycin, FK-506 reduced the effect of rapamycin on thrombin-induced TF expression (Figure 5). Indeed, when incubated with the highest concentration of FK-506 (10–7 mol/L), the increase in TF expression elicited by rapamycin with respect to stimulation with thrombin alone was reduced by 41% (P<0.05).
|
Effect of Rapamycin on Thrombin-Induced TF mRNA Levels
Real-time PCR revealed that thrombin induced TF mRNA expression in a time-dependent manner (Figure 6A). Rapamycin did not alter thrombin-induced mRNA expression compared with stimulation by thrombin alone after 0.5, 1, and 2 hours. However, after 3 and 5 hours of stimulation, rapamycin significantly augmented thrombin-induced TF mRNA levels (Figure 6A and 6B). Rapamycin significantly increased thrombin-induced TF protein expression after 3, 5, and 7 hours compared with stimulation by thrombin alone (Figure 6C).
|
Rapamycin did not affect the pattern of MAP kinase activation observed after thrombin stimulation. Indeed, phosphorylation of p38 (Figure 7A), ERK (Figure 7B), and JNK (Figure 7C) remained unaltered after pretreatment with rapamycin compared with stimulation by thrombin alone.
|
Rapamycin, but Not FK-506, Inhibits EC Proliferation
EC proliferation was induced by incubation with EBM containing 10% FCS (Figure 8A, control). Rapamycin (10–7 mol/L) prevented FCS-induced EC proliferation. In contrast, FK-506 (10–7 mol/L) did not significantly inhibit EC proliferation (Figure 8A).
|
TUNEL staining was used to examine whether rapamycin (10–7 mol/L) or FK-506 (10–7 mol/L) induced apoptosis in HAECs (Figure 8B). Representative sections are shown. After 24 hours, TUNEL-positive cells accounted for 5.3±0.7% of cells in the control group, 4.7±1.7% for rapamycin (P=NS versus control), and 4.8±1.5% for FK-506 (P=NS versus control). After 48 hours, 4.2±1.7% of control cells, 3.5±0.6% of rapamycin-treated cells (P=NS versus control), and 4.6±2.3% of FK-506-treated cells (P=NS versus control) were TUNEL-positive. Cells incubated with H2O2 (1 mmol/L) for 6 hours as well as serum withdrawal for 48 hours served as positive controls and resulted in a significant increase in apoptotic cells (data not shown). Thus, neither rapamycin (10–7 mol/L) nor FK-506 (10–7 mol/L) led to an increase in apoptotic cells compared with control conditions.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study demonstrates that rapamycin enhances endothelial TF expression in response to thrombin and TNF-
. The concentrations of rapamycin occurring in vivo compare well with those used in our study, as maximal systemic concentrations of rapamycin after deployment of 2 sirolimus-eluting stents are reported to be 1 ng/mL (1.15x10–9 mol/L)29; moreover, local concentrations, though difficult to assess, are likely to be significantly higher, partly because of rapamycin’s lipophilic properties, leading to accumulation of the drug in the vessel wall.11,30–32 Thus, the concentrations used in our study may be relevant for patients treated with DESs.
Reendothelialization is initiated soon after vascular injury; indeed, it has been observed to begin as early as 2 days after balloon dilation in animal models.33–35 In humans, partial reendothelialization has been documented 3 weeks after stent deployment.35–37 Sirolimus-eluting stents are designed in such a way that 80% of the rapamycin has eluted by 30 days.4,5 Furthermore, rapamycin easily penetrates cell walls owing to its lipophilic properties, leading to chronic retention of the drug in arterial tissue.30–32 Thus, the time course of reendothelialization versus the kinetics of rapamycin release suggests that rapamycin-enhanced endothelial TF expression may be involved in the pathogenesis of in-stent thrombosis. In addition, inhibition of endothelial proliferation by rapamycin indicates that rapamycin delays reendothelialization, which may increase stent thrombogenicity even further.
Several hundred cases of acute and subacute in-stent thrombosis have been observed after deployment of rapamycin-eluting stents.13 In addition and in contrast to BMSs, late thrombosis has been reported after withdrawal of antithrombotic drugs with DESs.10 Most of these data originated from case reports or were collected in controlled clinical trials. Recent results from a large-scale, multicenter registry, however, indicate that in-stent thrombosis is likely underestimated under these circumstances and that it may occur at substantially higher rates in real world patients.14 The pathogenesis of in-stent thrombosis has not yet been fully explored15; moreover, it is not known whether the pathogenic events leading to thromboses of DESs are similar to those of BMSs. Enhanced TF expression in the presence of rapamycin may indeed favor the development of in-stent thrombosis after deployment of sirolimus-eluting stents, particularly when clopidogrel is withdrawn or ineffective because of drug resistance.38 FK-506, which neither affects endothelial TF expression nor inhibits EC proliferation, may provide a more favorable environment for reducing thromboses of DESs. To assess the implications of these findings in vivo, however, further studies are needed to examine the degree as well as the spatiotemporal pattern of TF expression in the arterial wall after deployment of DESs.
Platelet activation is a crucial event in the pathogenesis of thrombus formation. Consequently, the use of platelet receptor blockers such as clopidogrel have greatly reduced the incidence of stent thromboses, whereas withdrawal of antiplatelet therapy favors thrombus formation.10,14 Moreover, clopidogrel inhibits the release of TF from aggregating platelets,39 which is of particular interest, as platelet aggregation and secretion are increased in human platelets treated with rapamycin.40 Thus, effective antiplatelet therapy may account for the fact that thrombosis rates of sirolimus-eluting stents are not clearly higher than those of BMSs.
TF induction after deployment of rapamycin-eluting stents may also have a prothrombotic effect on ECs distal to the stented site. Indeed, remote effects of rapamycin have been demonstrated, with pronounced endothelial dysfunction in coronary arteries distal to sirolimus-eluting stents compared with BMSs.41 Thus, in addition to the effect on ECs within the stented region, rapamycin may also increase TF expression in ECs in the distal coronary vasculature. Such an effect may also contribute to the no-reflow phenomenon after stent deployment.
Rapamycin did not enhance thrombin- or TNF-–driven TF expression in HAVSMCs, indicating that rapamycin does not constitute an additional thrombogenic signal to the VSMC layer. Indeed, a much higher incidence of acute and subacute stent thromboses would be expected if rapamycin induced TF expression in VSMCs. Although the rapamycin-induced increase in endothelial TF expression may favor neointima formation via the release of growth factors from aggregating platelets, the inhibitory effect of rapamycin on the proliferation and migration of VSMC is very likely to protect the vessel from such effects.7 Consistent with this interpretation, sirolimus-eluting stents reduce neointima formation despite inducing a procoagulative state owing to enhanced endothelial TF expression.
Both thrombin, a coagulation factor, and TNF-, an inflammatory cytokine, are classic inducers of TF expression in vascular cells. Thrombin induced TF expression 27-fold when examined by Western blotting analysis and 10.3-fold by ELISA; similarly, rapamycin enhanced thrombin-induced TF expression by 2.3-fold in Western blot analysis and 1.5-fold by ELISA. This difference may be due to a different sensitivity and/or specificity of the 2 assays. In our study, rapamycin enhanced TF expression in response to both thrombin and TNF-; it may thus upregulate TF expression in a prothrombotic as well as an inflammatory environment, both of which are encountered in the coronary vasculature after stent deployment.
Biologically active TF is located at the cell surface, and rapamycin-enhanced TF protein expression was indeed paralleled by an increase in TF surface activity. The increase in activity was not as pronounced as that of protein expression; this discrepancy has also been observed in response to thrombin alone.42 The distribution of TF in several cellular compartments and/or the expression of encrypted TF might account for this difference.43
The inhibitory role of phosphatidyl inositol 3-kinase on TF expression is established, as its inhibition enhances TF expression in response to thrombin.42,44 The mTOR is a downstream target of phosphatidyl inositol 3-kinase.28 Binding of rapamycin to its intracellular receptor FKBP-12 leads to formation of the rapamycin–FKBP-12 complex, which in turn inhibits mTOR activity. Phosphorylation of the downstream target of mTOR, S6K, is routinely used as a readout for the inhibitory effect of rapamycin on mTOR27,28; indeed, mTOR-dependent phosphorylation of the Thr-389 residue of S6K is necessary for its activity.27 In the present study, we have shown that stimulation with thrombin leads to a transient inhibition of S6K phosphorylation. Rapamycin as well as the phosphatidyl inositol 3-kinase inhibitors wortmannin and LY294002 abrogated S6K phosphorylation in both the presence and absence of thrombin. Because thrombin stimulation as well as preincubation with rapamycin led to inhibition of this pathway, resulting in disinhibition of TF expression, these observations are consistent with the interpretation that mTOR plays an inhibitory role in TF expression.
FK-506 competitively binds to the same intracellular receptor as rapamycin, ie, FKBP-12.45 In contrast to rapamycin, however, the FK-506–FKBP-12 complex inhibits the phosphatase calcineurin and has no effect on mTOR activity.46 Consistently, FK-506 did not alter thrombin- or TNF-–induced TF expression. To assess the specificity of our observations, we coincubated FK-506 and rapamycin before thrombin stimulation. The enhancing effect of rapamycin on thrombin-induced TF expression could indeed be reduced by FK-506. These findings indicate that binding of rapamycin to FKBP-12 is necessary for inhibition of mTOR activity and enhancement of TF expression.
TF expression in response to a variety of stimuli is mediated by MAP kinase activation, leading to increased transcription.22,24,42 Indeed, thrombin induced an increase in p38, ERK, and JNK phosphorylation as well as an increase in TF transcription. However, rapamycin did not alter the pattern of thrombin-induced p38, ERK, and JNK activation. Consistent with this observation, thrombin-induced mRNA levels were unchanged by rapamycin for up to 2 hours after stimulation. However, after 3 and 5 hours of thrombin stimulation, rapamycin increased mRNA levels compared with stimulation by thrombin alone. Taken together, these data imply that the enhancing effect of rapamycin on thrombin-induced TF expression initially occurs at the posttranscriptional level and hence, is independent of MAP kinase activation, although a transcriptional effect of rapamycin cannot be ruled out at later time points. Indeed, mTOR is known to exert posttranscriptional effects, and TF expression can be regulated at both the transcriptional and posttranscriptional level.47,48
In summary, our study reveals that rapamycin, but not FK-506, enhances endothelial TF expression and reduces HAEC proliferation. These effects may favor the development of thrombus formation after deployment of sirolimus-eluting stents, particularly when antithrombotic drugs are withdrawn or ineffective, and may have interesting implications for the design of DESs.
|
Acknowledgments |
|---|
This work was supported by the Swiss National Science Foundation (grant No. 3200B0-102232/1 to Dr Tanner and grant No. 3100-068118.02/1 to Dr Lüscher), the Bonizzi-Theler Foundation, the Hartmann-Müller Foundation, the Herzog-Egli Foundation, and the Olga Mayenfisch Foundation. The authors thank Dr F. Eberli and Dr W. Maier for discussion.
|
Footnotes |
|---|
*The first 2 authors contributed equally to the study.
Guest Editor for this article was James T. Willerson, MD.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000; 343: 385–391.
2. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O’Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction: Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999; 341: 1949–1956.
3. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999; 341: 319–327.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–1780.
5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–1323.
6. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004; 364: 583–591.[CrossRef][Medline] [Order article via Infotrieve]
7. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999; 99: 2164–2170.
8. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery: everolimus- and tacrolimus-eluting stents. Herz. 2004; 29: 162–166.[CrossRef][Medline] [Order article via Infotrieve]
9. Bartorelli AL, Trabattoni D, Fabbiocchi F, Montorsi P, de Martini S, Calligaris G, Teruzzi G, Galli S, Ravagnani P. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Interv Cardiol. 2003; 16: 499–505.[CrossRef][Medline] [Order article via Infotrieve]
10. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519–1521.[CrossRef][Medline] [Order article via Infotrieve]
11. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004; 5: 9–15.[CrossRef][Medline] [Order article via Infotrieve]
12. Eisenberg MJ. Drug-eluting stents: some bare facts. Lancet. 2004; 364: 1466–1467.[CrossRef][Medline] [Order article via Infotrieve]
13. FDA advises physicians of adverse events associated with Cordis Cypher coronary stents. US Food and Drug Administration Public Health Web Notification. October 29, 2003:T03-T71.
14. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126–2130.
15. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003; 108: 2–5.
16. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002; 53: 313–325.
17. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost. 1996; 75: 389–392.[Medline] [Order article via Infotrieve]
18. Tutar E, Ozcan M, Kilickap M, Gulec S, Aras O, Pamir G, Oral D, Dandelet L, Key NS. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation. 2003; 108: 1581–1584.
19. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993; 91: 2253–2259.[Medline] [Order article via Infotrieve]
20. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, Tanner FC. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005; 111: 1685–1689.
21. Tanner FC, Greutert H, Barandier C, Frischknecht K, Luscher TF. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension. 2003; 42: 184–188.
22. Steffel J, Akhmedov A, Greutert H, Lüscher TF, Tanner FC. Histamine induces tissue factor: implications for acute coronary syndromes. Circulation. 2005; 112: 341–349.
23. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998; 82: 396–403.
24. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9: 458–462.[CrossRef][Medline] [Order article via Infotrieve]
25. Cui MZ, Zhao G, Winokur AL, Laag E, Bydash JR, Penn MS, Chisolm GM, Xu X. Lysophosphatidic acid induction of tissue factor expression in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003; 23: 224–230.
26. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor-
B, and Egr-1. J Biol Chem. 2002; 277: 25032–25039.
27. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A. 1998; 95: 1432–1437.
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926–1945.
29. US Food and Drug Administration, Center for Devices and Radiological Health. Cypher Sirolimus-eluting coronary stent on RAPTOR over-the-wire delivery system or RAPTORRAIL rapid exchange delivery system. Available at http://www.fda.gov/cdrh/pdf2/p020026.html. Accessed December 17, 2004.
30. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 1999; 10: 1366–1380.
31. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002; 13: 183–188.[CrossRef][Medline] [Order article via Infotrieve]
32. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001; 104: 1188–1193.
33. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation. 1996; 94: 3291–3302.
34. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, Libby P. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation. 1993; 88: 1788–1803.
35. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004; 44: 1373–1385.
36. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99: 44–52.
37. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000; 35: 157–163.
38. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171–3175.
39. Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A, Spannagl M, Gachet C, Engelmann B. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2004; 103: 594–600.
40. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant. 1998; 13: 3153–3159.
41. Hofma SH, Van der Giessen WJ, Van Dalen B, Lemos PA, Serruys PW Prolonged endothelial dysfunction late after stenting with sirolimus-eluting stent compared to bare metal stent. Eur Heart J. 2004; 25 (suppl): 525.Abstract.
42. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105: 1756–1759.
43. Schecter AD, Spirn B, Rossikhina M, Giesen PL, Bogdanov V, Fallon JT, Fisher EA, Schnapp LM, Nemerson Y, Taubman MB. Release of active tissue factor by human arterial smooth muscle cells. Circ Res. 2000; 87: 126–132.
44. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergeres G, Rusconi S, Yang Z. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res. 2004; 94: 918–925.
45. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990; 87: 9231–9235.
46. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807–815.[CrossRef][Medline] [Order article via Infotrieve]
47. Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, Suzuki K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 1997; 90: 2345–2356.
48. Lopez-Pedrera C, Jardi M, Ingles-Esteve J, Munoz-Canoves P, Dorado G, Velasco F, Felez J. Characterization of tissue factor expression on the human endothelial cell line ECV304. Am J Hematol. 1997; 56: 71–78.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  G. S. Mintz and S.-Y. Choi Optimal Stent Expansion and Complete Neointimal Coverage: Does This Association Make Sense? J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 995 - 996. [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T. F. Luscher, and F. C. Tanner Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents Eur. Heart J., June 29, 2009; (2009) ehp259v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ota, M. Eto, J. Ako, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2298 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Onuma, P. Serruys, P. den Heijer, K. S. Joesoef, H. Duckers, E. Regar, N. Kukreja, S. Tanimoto, H. M. Garcia-Garcia, H. van Beusekom, et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses Eur. Heart J., June 2, 2009; 30(12): 1477 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chandrashekhar, M. J. Kern, and J. Narula Devices, biology, imaging, and the regulatory processes... J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 670 - 673. [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Stahli, G. G. Camici, and F. C. Tanner Drug-eluting stent thrombosis Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 45 - 52. [Abstract] [PDF]
|
|
|
|
|
|
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al. Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1134 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija, Q. Cheng, X. Xu, et al. Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents J. Am. Coll. Cardiol., July 29, 2008; 52(5): 333 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2123 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M.W. Verheul, B. Salumbides, K. Van Erp, H. Hammers, D. Z. Qian, T. Sanni, P. Atadja, and R. Pili Combination Strategy Targeting the Hypoxia Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors Clin. Cancer Res., June 1, 2008; 14(11): 3589 - 3597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barilli, R. Visigalli, R. Sala, G. C. Gazzola, A. Parolari, E. Tremoli, S. Bonomini, A. Simon, E. I. Closs, V. Dall'Asta, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function Cardiovasc Res, June 1, 2008; 78(3): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]
|
|
|
|
 |
|
 B. E. Stahli, A. Breitenstein, A. Akhmedov, G. G. Camici, K. Shojaati, N. Bogdanov, J. Steffel, D. Ringli, T. F. Luscher, and F. C. Tanner Cardiac Glycosides Regulate Endothelial Tissue Factor Expression in Culture Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2769 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Windecker and B. Meier Late Coronary Stent Thrombosis Circulation, October 23, 2007; 116(17): 1952 - 1965. [Full Text] [PDF]
|
|
|
|
|
|
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? Circulation, July 17, 2007; 116(3): 316 - 328. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Finn, G. Nakazawa, M. Joner, F. D. Kolodgie, E. K. Mont, H. K. Gold, and R. Virmani Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1500 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher, J. Steffel, F. R. Eberli, M. Joner, G. Nakazawa, F. C. Tanner, and R. Virmani Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications Circulation, February 27, 2007; 115(8): 1051 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Camici, J. Steffel, A. Akhmedov, N. Schafer, J. Baldinger, U. Schulz, K. Shojaati, C. M. Matter, Z. Yang, T. F. Luscher, et al. Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation: A Potential Treatment Strategy for Drug-Eluting Stents Circulation, October 3, 2006; 114(14): 1512 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takano, T. Ohba, S. Inami, K. Seimiya, S. Sakai, and K. Mizuno Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation Eur. Heart J., September 2, 2006; 27(18): 2189 - 2195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Stahli, G. G. Camici, J. Steffel, A. Akhmedov, K. Shojaati, M. Graber, T. F. Luscher, and F. C. Tanner Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation Circ. Res., July 21, 2006; 99(2): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||